Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers predicting treatment outcome in depression: what is clinically significant?

Pharmacogenomics - 1 Jan 2012

Uher Rudolf, Tansey Katherine E, Malki Karim, Perlis Roy H

Abstract excerpt

AIM: To extend to biomarker studies the consensus clinical significance criterion of a three-point difference in Hamilton Rating Scale for Depression. MATERIALS & METHODS: We simulated datasets modeled on large clinical trials. RESULTS: In a typical clinical trial comparing active treatment and placebo, a difference of three Hamilton Rating Scale for Depression (HRSD) points at the end of treatment corresponds to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Biomarkers, Pharmacological
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Cost-Benefit Analysis

Share to Depression

Share to Reference Standards

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 22256872
DOI: 10.2217/pgs.11.161
PMCID: PMC3566553

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers predicting treatment outcome in depression: what is clinically significant?PMID 22256872Read ↗

The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response Study: Design and MethodologySemantic proximity Read ↗

The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction.Semantic proximity Read ↗

Advancing Depression Management Through Biomarker Discovery with a Focus on Genetic and Epigenetic Aspects: A Comprehensive Study on Neurobiological, Neuroendocrine, Metabolic, and Inflammatory PathwaysSemantic proximity Read ↗

Pharmacogenetic studies in depression: a proposal for methodologic guidelines.Semantic proximity Read ↗

Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.Semantic proximity Read ↗

Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response MarkersSemantic proximity Read ↗

Are there meaningful biomarkers of treatment response for depression?Semantic proximity Read ↗

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant responseSemantic proximity Read ↗

Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.Semantic proximity Read ↗

Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.Semantic proximity Read ↗

Individualized Treatment Strategy for Depressive Disorder.Semantic proximity Read ↗

Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.